# An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

> **NCT01803867** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 72 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** rHIgM22

## Key facts

- **NCT ID:** NCT01803867
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-10
- **Final completion:** 2015-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803867, "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01803867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*